Bafna Pharmaceuticals announces upgradation of credit ratings

From CRISIL

Bafna Pharmaceuticals announced that CRISIL has upgraded the rating as CRISIL BB-/stable (Upgraded from CRISIL D) for Long Term rating & CRISIL A4+ (Upgraded from CRISIL D) for Short term Rating in respect of Total bank facilities.

Powered by Capital Market - Live News